NASDAQ · MODD

Modular Medical, Inc.

$2.31 -$0.20 (-7.97%) 1D Market open

Key Metrics

$13.59M
Market cap
P/E · TTM
Revenue · TTM
−$28.24M
Net income
EPS · TTM $-22.91
Dividend yield
Free cash flow −$27.69M
Beta · 1Y 1.68
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Feb 19 high, the share price fell 85%.

    Peak close $15.27 on Feb 19; trough close $2.31 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -85%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 2
    The stock moved -36.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2
  • Feb 27
    The stock moved -45.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$13.59M
Enterprise value
Shares outstanding5.4M
52-wk range$0.28 – $16.20
Avg volume · 20D189.4K
Net cash
Book value / share$10.51
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Modular Medical, Inc.
IPO dateFeb 10, 2022
Employees51

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -188.1% · -469.4%

Financial Health

Current ratio4.03
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.67M

Cash Flow · TTM

Operating CF −$23.75M
Capex −$3.93M
Free cash flow −$27.69M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings